AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (1.4 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Publishing Language: Chinese

Research Progress on the Risk of Excipients-Related Adverse Reactions in Pharmaceutical Preparations for IBD Treatment

Yanru ZHANG1Qiuyue TU1Ping WANG2Zelin FENG1Huizhen LI1Yushan ZHU3Haojia LIN1Xinyue WEI1Qinghua YI1Hetong ZHANG1Yueting LI1Xiaoqin LI1Yu WANG1Dong XIE4( )Xiaocang CAO1,5( )
Department of Gastroenterology, General Hospital of Tianjin Medical University, Tianjin 300052, China
Department of Pharmacy, Beichen Hospital of Tianjin, Tianjin 300499, China
School of Pharmacy, Tianjin Medical University, Tianjin 300052, China
Department of Pharmacy, General Hospital of Tianjin Medical University, Tianjin 300052, China
Department of Gastroenterology, Shenzhen Hospital of Southern Medical University, Shenzhen 518000, China
Show Author Information

Abstract

Patients with inflammatory bowel disease (IBD) require long-term pharmacotherapy. Due to the wide variety of clinically available drugs, medication safety has become increasingly concerning. As an indispensable component of pharmaceutical formulations, drug excipients may induce various adverse reactions, including rash, allergic responses, and gastrointestinal discomfort, and may even lead to severe organic injury. However, they are often overlooked in clinical practice. Therefore, identifying and managing excipient-related adverse reactions is crucial for ensuring medication safety. To address this issue, this article systematically reviews common excipients in IBD therapeutics, the underlying mechanisms of excipient-induced adverse reactions, and corresponding management strategies, aiming to enhance clinicians' awareness of excipient-related issues, improve their ability to recognize and manage such reactions, and ultimately ensure patient safety.

CLC number: R574; R969 Document code: A Article ID: 1674-9081(2026)04-1135-08

References

【1】
【1】
 
 
Medical Journal of Peking Union Medical College Hospital
Pages 1135-1142

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
ZHANG Y, TU Q, WANG P, et al. Research Progress on the Risk of Excipients-Related Adverse Reactions in Pharmaceutical Preparations for IBD Treatment. Medical Journal of Peking Union Medical College Hospital, 2026, 17(4): 1135-1142. https://doi.org/10.12290/xhyxzz.2025-0748

6

Views

0

Downloads

0

Crossref

0

Scopus

0

CSCD

Received: 30 July 2025
Accepted: 22 January 2026
Published: 20 July 2026
© 2026 Medical Journal of Peking Union Medical College Hospital